AR127585A1 - Vacuna de arn de virus sincicial respiratorio - Google Patents
Vacuna de arn de virus sincicial respiratorioInfo
- Publication number
- AR127585A1 AR127585A1 ARP220103037A ARP220103037A AR127585A1 AR 127585 A1 AR127585 A1 AR 127585A1 AR P220103037 A ARP220103037 A AR P220103037A AR P220103037 A ARP220103037 A AR P220103037A AR 127585 A1 AR127585 A1 AR 127585A1
- Authority
- AR
- Argentina
- Prior art keywords
- rsv
- vaccine
- virus rna
- rna vaccine
- eliciting
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 4
- 108700026244 Open Reading Frames Proteins 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 108020004999 messenger RNA Proteins 0.000 abstract 2
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 abstract 1
- 229940124679 RSV vaccine Drugs 0.000 abstract 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
- C07K14/135—Respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163276233P | 2021-11-05 | 2021-11-05 | |
| EP22315065 | 2022-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127585A1 true AR127585A1 (es) | 2024-02-07 |
Family
ID=84357817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220103037A AR127585A1 (es) | 2021-11-05 | 2022-11-04 | Vacuna de arn de virus sincicial respiratorio |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230302112A1 (https=) |
| EP (1) | EP4426343A1 (https=) |
| JP (1) | JP2024542085A (https=) |
| KR (1) | KR20240107146A (https=) |
| AR (1) | AR127585A1 (https=) |
| AU (1) | AU2022382104A1 (https=) |
| CA (1) | CA3236924A1 (https=) |
| CO (1) | CO2024005145A2 (https=) |
| IL (1) | IL312334A (https=) |
| MX (1) | MX2024005462A (https=) |
| TW (1) | TW202346593A (https=) |
| WO (1) | WO2023079507A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022099003A1 (en) | 2020-11-06 | 2022-05-12 | Sanofi | Lipid nanoparticles for delivering mrna vaccines |
| JP2024530672A (ja) | 2021-08-11 | 2024-08-23 | アールエヌエーイミューン、インコーポレイテッド | 新規なコロナウイルス感染症に対するｍＲＮＡワクチンの組成物および方法 |
| US12280104B2 (en) | 2022-11-01 | 2025-04-22 | RNAimmune, Inc. | Composition and methods for MRNA vaccines against novel omicron coronavirus infections |
| EP4734960A1 (en) * | 2023-06-28 | 2026-05-06 | Sanofi Pasteur Inc. | Sterol analogs in lipid nanoparticle formulations |
| EP4734959A1 (en) * | 2023-06-28 | 2026-05-06 | Sanofi Pasteur Inc. | Use of glycerides for lnp formulations |
| WO2025024336A1 (en) * | 2023-07-21 | 2025-01-30 | RNAimmune, Inc. | Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines |
| CN119490569A (zh) * | 2023-08-16 | 2025-02-21 | 深圳瑞吉生物科技有限公司 | 呼吸道合胞病毒抗原性多肽、核酸、疫苗及其应用 |
| CN119504955A (zh) * | 2023-08-25 | 2025-02-25 | 深圳瑞吉生物科技有限公司 | 呼吸道合胞病毒抗原性多肽、核酸及疫苗 |
| CN119979573A (zh) * | 2023-11-03 | 2025-05-13 | 纳美信(上海)生物科技有限公司 | 一种呼吸道合胞病毒mRNA疫苗 |
| CN120022355A (zh) * | 2023-11-22 | 2025-05-23 | 长春百克生物科技股份公司 | 一种mRNA疫苗及其应用 |
| CN120227354A (zh) * | 2023-12-29 | 2025-07-01 | 康希诺(上海)生物研发有限公司 | 一种用于递送核酸的脂质纳米颗粒及其制备方法和用途 |
| CN118440937B (zh) * | 2024-04-09 | 2025-02-25 | 嘉译生物医药(杭州)有限公司 | 新型的人合胞病毒RSV B mRNA疫苗 |
| CN119144620B (zh) * | 2024-08-29 | 2025-08-19 | 北京康乐卫士生物技术股份有限公司 | 呼吸道合胞病毒mRNA疫苗及其制备方法和应用 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| EP1167379A3 (en) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
| AU760549B2 (en) | 1998-04-03 | 2003-05-15 | University Of Iowa Research Foundation, The | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| CN1989250B (zh) | 2004-05-18 | 2013-11-20 | 阿尔法瓦克斯公司 | Tc-83衍生的甲病毒属载体、颗粒和方法 |
| CA2766907A1 (en) | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
| EP3318248B1 (en) | 2009-12-01 | 2019-04-10 | Translate Bio, Inc. | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
| US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| RU2013154295A (ru) | 2011-06-08 | 2015-07-20 | Шир Хьюман Дженетик Терапис, Инк. | КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК |
| PE20181541A1 (es) | 2011-10-27 | 2018-09-26 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco |
| EP2858679B2 (en) | 2012-06-08 | 2024-06-05 | Translate Bio, Inc. | Pulmonary delivery of mrna to non-lung target cells |
| US9738689B2 (en) * | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| BR112015022505A2 (pt) | 2013-03-14 | 2017-10-24 | Shire Human Genetic Therapies | avaliação quantitativa para eficiência do cap de rna mensageiro |
| EP3388834B1 (en) | 2013-03-15 | 2020-04-15 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| KR102354389B1 (ko) | 2013-08-21 | 2022-01-20 | 큐어백 아게 | Rna―암호화된 단백질의 발현을 증가시키는 방법 |
| WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
| CN111304231A (zh) | 2013-12-30 | 2020-06-19 | 库瑞瓦格股份公司 | 人工核酸分子 |
| CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
| BR112016030852A2 (pt) | 2014-07-02 | 2018-01-16 | Shire Human Genetic Therapies | encapsulação de rna mensageiro |
| PT4023755T (pt) | 2014-12-12 | 2023-07-05 | CureVac SE | Moléculas de ácido nucleico artificiais para uma expressão melhorada de proteína |
| ES2897823T3 (es) | 2015-04-30 | 2022-03-02 | Curevac Ag | Poli(N)polimerasa inmovilizada |
| WO2016205691A1 (en) | 2015-06-19 | 2016-12-22 | Massachusetts Institute Of Technology | Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell |
| EP4011451A1 (en) * | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
| CA3043033A1 (en) | 2016-11-10 | 2018-05-17 | Translate Bio, Inc. | Improved ice-based lipid nanoparticle formulation for delivery of mrna |
| AU2017357758B2 (en) | 2016-11-10 | 2023-11-16 | Translate Bio, Inc. | Improved process of preparing mRNA-loaded lipid nanoparticles |
| EP3595713A4 (en) * | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS Vaccine |
| EP3746090A4 (en) * | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | RSV RNA Vaccines |
| JP7614841B2 (ja) | 2018-04-03 | 2025-01-16 | サノフイ | 抗原性呼吸器合胞体ウイルスポリペプチド |
| KR20210105889A (ko) * | 2018-11-09 | 2021-08-27 | 아뷰터스 바이오파마 코포레이션 | 지질 나노입자 제제 |
| CA3146675A1 (en) | 2019-07-23 | 2021-01-28 | Translate Bio, Inc. | Stable compositions of mrna-loaded lipid nanoparticles and processes of making |
-
2022
- 2022-11-04 MX MX2024005462A patent/MX2024005462A/es unknown
- 2022-11-04 AU AU2022382104A patent/AU2022382104A1/en active Pending
- 2022-11-04 EP EP22802727.2A patent/EP4426343A1/en active Pending
- 2022-11-04 TW TW111142195A patent/TW202346593A/zh unknown
- 2022-11-04 IL IL312334A patent/IL312334A/en unknown
- 2022-11-04 CA CA3236924A patent/CA3236924A1/en active Pending
- 2022-11-04 US US18/052,600 patent/US20230302112A1/en active Pending
- 2022-11-04 KR KR1020247018527A patent/KR20240107146A/ko active Pending
- 2022-11-04 JP JP2024526560A patent/JP2024542085A/ja active Pending
- 2022-11-04 AR ARP220103037A patent/AR127585A1/es unknown
- 2022-11-04 WO PCT/IB2022/060639 patent/WO2023079507A1/en not_active Ceased
-
2024
- 2024-04-24 CO CONC2024/0005145A patent/CO2024005145A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3236924A1 (en) | 2023-05-11 |
| US20230302112A1 (en) | 2023-09-28 |
| KR20240107146A (ko) | 2024-07-08 |
| CO2024005145A2 (es) | 2024-07-08 |
| TW202346593A (zh) | 2023-12-01 |
| MX2024005462A (es) | 2024-05-22 |
| IL312334A (en) | 2024-06-01 |
| WO2023079507A1 (en) | 2023-05-11 |
| AU2022382104A1 (en) | 2024-06-20 |
| JP2024542085A (ja) | 2024-11-13 |
| EP4426343A1 (en) | 2024-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR127585A1 (es) | Vacuna de arn de virus sincicial respiratorio | |
| PH12021550479A1 (en) | Dengue vaccine unit dose and administration thereof | |
| JOP20220349A1 (ar) | توليفة لقاح ضد الإصابة بفيروس مخلوي تنفسي | |
| MX2017014127A (es) | Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos. | |
| MX2016016533A (es) | Combinaciones inmunogenas. | |
| MX2015013065A (es) | Proteinas f de rsv de prefusion y su uso. | |
| MX2022010460A (es) | Vacunas contra el coronavirus y metodos de uso. | |
| EA201171032A1 (ru) | Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами | |
| MX2019003682A (es) | Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas. | |
| MX2024006506A (es) | Vacunas basadas en vectores virales de metapneumovirus humano. | |
| BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
| CA3242439A1 (en) | Lyme disease rna vaccine | |
| UY40490A (es) | Vacunas de combinación para prevenir y/o tratar múltiples agentes infecciosos | |
| MX2025005156A (es) | Vacuna de arn contra el virus respiratorio sincicial | |
| UY40331A (es) | Vacuna contra el coronavirus | |
| CL2024003287A1 (es) | Virus para vacuna contra el síndrome respiratorio y reproductivo porcino. | |
| CL2020002876A1 (es) | Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420) | |
| BR112022007474A2 (pt) | Vacina de partículas semelhantes a vírus chikungunya e métodos de uso da mesma | |
| BR112022020100A2 (pt) | Vacina inativada contra vírus sars-cov-2 | |
| MX2020001055A (es) | Vacuna contra la malaria. | |
| MX2021015155A (es) | Polisacaridos de ramnosa. | |
| AR130779A1 (es) | Vacunas de combinación | |
| MX2023011784A (es) | Metodo para provocar una respuesta inmunitaria contra virus sincitial respiratorio. | |
| PY2384842A (es) | Vacunas de combinación.- | |
| AR127807A1 (es) | Vacuna contra el coronavirus |